MARTIN ESTLE SANDERS
Medical Practice in Burlingame, CA
License number
Pennsylvania MD047842L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Burlingame, CA 94010
Pennsylvania
Pennsylvania
Personal information
See more information about MARTIN ESTLE SANDERS at radaris.comName
Address
Phone
594 63Rd St APT 4, Oakland, CA 94609
5836 Indian Pointe Dr, Simi Valley, CA 93063
5700 Lochmoor Dr APT 119, Riverside, CA 92507
3721 Oakton Rd, Pittsburgh, PA 15227
420 El Centro Rd, Hillsborough, CA 94010
Professional information
Treatment Of B Cell Diseases Using Anti-Germline Antibody Binding Agents
US Patent:
2007008, Apr 12, 2007
Filed:
Sep 19, 2006
Appl. No.:
11/524531
Inventors:
Martin Sanders - Hillsborough CA, US
International Classification:
A61K 39/395, G01N 33/567, A61K 39/00
US Classification:
424131100, 435007200, 424140100
Abstract:
Methods for reducing the number of pathologic antibody producing B cells in a patient suffering from an autoimmune disease by administration of an anti-germline antibody are described. Methods for removing pathologic antibodies and B cells and plasma cells producing pathologic antibodies from the body of a patient suffering from autoimmune disease are provided, comprising contacting the blood or plasma of the patient with an immunoadsorbent having specific binding for an epitope present on germline antibodies, particularly VH4-34 antibodies, wherein said contacting results in the reduction in the amount of germline antibodies present in the blood or bone marrow or lymphoid tissue of the patient or the amount of germline antibody producing B cells present in the blood, lymphoid tissues or bone marrow of the patient. Methods for treating a patient suffering from a B cell cancer expressing cell surface germline antibodies by similar methods are also provided. Methods for ex vivo purging bone marrow of pathologic antibody producing B-cells and cancerous B-cells expressing germline antibodies are provided. Methods for monitoring the efficacy of a therapeutic treatment in a patient suffering from an autoimmune disease or B cell cancer are also provided. Kits and uses in preparation of a medicament are also described.
Method For Increasing Sex Steroid Levels Using Igf Or Igf/Igfbp-3
US Patent:
6015786, Jan 18, 2000
Filed:
Apr 21, 1997
Appl. No.:
8/837603
Inventors:
Desmond Mascarenhas - Los Altos Hills CA
Martin Sanders - Hillsborough CA
Martin Sanders - Hillsborough CA
Assignee:
Celtrix Pharmaceuticals, Inc. - San Jose CA
International Classification:
A61K 3830
US Classification:
514 12
Abstract:
Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.
Method For Treating The Symptoms Of Chronic Stress-Related Disorders Using Igf
US Patent:
6025368, Feb 15, 2000
Filed:
Feb 25, 1997
Appl. No.:
8/805807
Inventors:
Desmond Mascarenhas - Los Altos Hills CA
Martin Sanders - Hillsborough CA
Martin Sanders - Hillsborough CA
Assignee:
Celtrix Pharmaceuticals, Inc. - San Jose CA
International Classification:
A01N 4342
US Classification:
514310
Abstract:
Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF alone or complexed with IGFBP-3 are additionally provided.
Methods For Avoiding Edema In The Treatment Or Prevention Of Pparγ-Responsive Diseases, Including Cancer
US Patent:
8288438, Oct 16, 2012
Filed:
Mar 21, 2006
Appl. No.:
11/908952
Inventors:
Martin E. Sanders - Hillsborough CA, US
David B. Karpf - Monte Sereno CA, US
David B. Karpf - Monte Sereno CA, US
Assignee:
Metabolex, Inc. - Hayward CA
Dia Tex, Inc. - San Antonio TX
Dia Tex, Inc. - San Antonio TX
International Classification:
A61K 31/20
US Classification:
514559
Abstract:
Compounds, compositions, and methods of avoiding edema while treating or preventing PPARγ-mediated diseases, including cancer, using derivatives and prodrugs are provided.
Methods For Avoiding Edema In The Treatment Of Metabolic, Inflammatory, And Cardiovascular Disorders
US Patent:
2008019, Aug 14, 2008
Filed:
Mar 21, 2006
Appl. No.:
11/908954
Inventors:
Martin E. Sanders - Hillsborough CA, US
David B. Karpf - Monte Sereno CA, US
David B. Karpf - Monte Sereno CA, US
International Classification:
A61K 31/44, A61K 31/216, A61K 31/4192, A61P 3/04, A61P 3/10, A61P 9/00, A61K 31/192
US Classification:
514354, 514533, 514571, 514359
Abstract:
Compounds, compositions, and methods of treating or preventing PPARγ-mediated diseases, including cancer, using phenoxy acetic acid derivatives and prodrugs are provided.
Treatment Of Endotoxemia Using Endotoxin Neutralizing Agents
US Patent:
2008003, Feb 7, 2008
Filed:
Feb 6, 2007
Appl. No.:
11/703538
Inventors:
Martin Sanders - Hillsborough CA, US
International Classification:
A61K 39/40, A61K 39/00, A61P 43/00, C12Q 1/00
US Classification:
424133100, 424150100, 424164100, 435004000
Abstract:
Methods and compositions for selecting a patient suffering from endotoxemia for treatment with an endotoxin neutralizing agent are disclosed comprising: (a) determining the level of endotoxin in the patient's blood; and (b) comparing the endotoxin level in the patient's blood to a predetermined threshold endotoxin level to determine if the patient has elevated endotoxin levels. The methods can further comprise treating patients identified as having elevated levels of endotoxin with an endotoxin neutralizing therapy. The methods provide increased safety and a reduction in risk for critically ill patients.
Enhanced B Cell Cytotoxicity Of Cdim Binding Antibody
US Patent:
2005011, May 26, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/982698
Inventors:
Neelima Bhat - Los Altos CA, US
Marcia Bieber - Los Altos CA, US
Nelson Teng - Hillsborough CA, US
Martin Sanders - Hillsborough CA, US
Marcia Bieber - Los Altos CA, US
Nelson Teng - Hillsborough CA, US
Martin Sanders - Hillsborough CA, US
International Classification:
A61K039/395, A61K039/42
US Classification:
424155100, 424159100, 514002000
Abstract:
Formulations and methods of treating human patients suffering from a condition characterized by lymphoid cancer, autoimmune disease or B cell hyperproliferation are disclosed, the treatment comprising administering (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a cytotoxic agent, including a chemotherapeutic agent, radioactive isotope, cytotoxic antibody, immunoconjugate, ligand conjugate, immunosuppressant, cell growth regulator and/or inhibitor, toxin, or mixtures thereof, including agents that disrupt the cytoskeleton of B cells, particularly vinca alkaloids or colchicine.
Antibody Induced Cell Membrane Wounding
US Patent:
2013016, Jun 27, 2013
Filed:
Feb 19, 2013
Appl. No.:
13/770619
Inventors:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA, US
Marcia M. Bieber - Los Altos CA, US
Nelson N.H. Teng - Hillsborough CA, US
Martin E. Sanders - Hillsborough CA, US
Marcia M. Bieber - Los Altos CA, US
Nelson N.H. Teng - Hillsborough CA, US
Martin E. Sanders - Hillsborough CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/395, A61K 31/704, A61K 38/50, A61K 31/475
US Classification:
4241331, 4241741, 4241581
Abstract:
Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell killing are provided. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. Preferably, the cell surface antigen is associated with the cytoskeleton of the cell. A preferred polyvalent agent is an IgM, and enhanced cell wounding and killing can be provided by the addition of a crosslinking agent. At sublethal concentrations in vivo, the cell wounding antibodies permeabilize cells and dramatically enhance response to chemotherapeutic agents, even in patients refractory to the chemotherapeutic agents.
Method For Treating Dementia Or Alzheimer's Disease
US Patent:
2009022, Sep 10, 2009
Filed:
Apr 17, 2009
Appl. No.:
12/425537
Inventors:
Martin E. Sanders - Hillsborough CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61P 25/28
US Classification:
4241331, 4241721
Abstract:
Methods for treating Alzheimer's disease (AD) or dementia using a CD20 antibody are described. Articles of manufacture for use in such methods are also described.
Method For Treating Dementia Or Alzheimer's Disease
US Patent:
2006024, Oct 26, 2006
Filed:
Apr 20, 2006
Appl. No.:
11/407726
Inventors:
Martin Sanders - Hillsborough CA, US
International Classification:
A61K 39/395, A61K 31/55, A61K 31/445
US Classification:
424144100, 514214010, 514319000
Abstract:
Methods for treating Alzheimer's disease (AD) or dementia using a CD20 antibody are described. Articles of manufacture for use in such methods are also described.